Nurix Therapeutics, Inc.
NRIXDrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Oct 8, 2026
19dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
How NRIX's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
NX-5948 | Phase 2 | Chronic Lymphocytic Leukemia (CLL) | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Nurix Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Nurix Therapeutics, Inc.'s (NRIX) pipeline across Phase 2. Its lead program is NX-5948 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Nurix Therapeutics, Inc.'s next FDA catalyst?→
Nurix Therapeutics, Inc.'s (NRIX) next tracked catalyst is a Earnings expected October 8, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track NRIX biotech catalysts?→
Add NRIX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Nurix Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.